February 16,2006

Senator Grassley's Statement for the Record regarding FDA's Approval Process

Please see the following two documents attached as related files:

(1) Grassley Statement from the Feb. 16 Congressional Record
(2) Report of the Committee Staff Review of the FDA’s Approval Process for the Vagus Nerve Stimulation Therapy System for Treatment-Resistant Depression

Next Article Previous Article

Recent News

05/27/25 Crapo Announces Nominations Hearing
05/20/25 Crapo Statement at IRS Commissioner Nomination Hearing
05/15/25 Finance Committee Advances HHS Nominations
05/15/25 Crapo Statement at Executive Session to Consider HHS Nominations
05/14/25 Crapo Applauds House Committee Markups Advancing President Trump’s Economic Agenda